💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Levobupivacaine

CHEMBL1201193 Phase 4 승인됨 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
288.4 g/mol
LogP
3.4
Phase
4

The S-enantiomer of bupivacaine, a long-acting local anesthetic used for regional anesthesia and pain management. It is considered to have a better safety profile than racemic bupivacaine, particularly regarding cardiac toxicity.

분자량

288.4000 g/mol

LogP

3.40

TPSA

32.30 Ų

리핀스키 5의 법칙

통과

치료 영역

Bladder Cancer Endometriosis Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Chronic Kidney Disease Stroke Obesity Hypertension Breast Cancer Chronic Pain Colorectal Cancer

작용 기전

Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C

                

                

                
                

                    
InChI

                    
InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)/t16-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C18H28N2O

                    

                    
                    

                        
HBD / HBA

                        
1 / 2

                    

                    
                    

                        
회전 가능 결합

                        
5

                    

                    
                    
                    

                        
무거운 원자

                        
21

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
The S-enantiomer of bupivacaine, a long-acting local anesthetic used for regional anesthesia and pain management. It is considered to have a better safety profile than racemic bupivacaine, particularly regarding cardiac toxicity.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Levobupivacaine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1201193.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 92253.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.